forzinity Heart Failure Research: The PROGRESS-HF Summary
Disclaimer: All content on this site is based on public academic research and clinical data for educational and informational reference only. It is not medical advice. No treatment or health-related decisions should be made based solely on website content. This site does not sell pharmaceuticals or endorse any medical treatment.
PROGRESS-HF: design and result
PROGRESS-HF was the elamipretide program in heart failure with reduced ejection fraction — daily subcutaneous administration, a broad cardiology population, and standard heart-failure outcome measurement. The program completed and did not meet its primary endpoint. That result closed the heart-failure investigation for the molecule; nothing in the current forzinity label derives from it, and no heart-failure indication exists. The trial's place in the global record is documented in the trials pillar.
This page exists because “forzinity heart failure” is a standing search pattern, and searchers deserve the accurate version: an investigational program that ran, completed, and did not confirm benefit — not a product feature, not a side note to the label, and not something to be laundered into implied relevance by proximity. Negative results are evidence, and we document them at full strength.
Why the program was scientifically credible — and still null
The heart-failure hypothesis was not speculative: cardiac bioenergetics is where ss-31's preclinical literature was strongest, with documented membrane and supercomplex effects in cardiac models (summarized on our mechanism page). PROGRESS-HF was the translation test of that literature — and the answer was that membrane-level effects in multifactorial heart failure did not reach the primary endpoint.
The scientific lesson generalizes across this molecule's record: the same mechanism that yields its clearest signal in a cardiolipin-deficiency population (Barth syndrome, per the Barth page) yields nulls in broad populations. Mechanism-expression appears population-dependent — an interpretation the literature discusses and we mark as interpretation, distinct from the endpoint data itself.
How to read a null result correctly
A null trial is data with structure: design, population, regimen as published, endpoint definition, and result. What it is not is a negation of the molecule's other evidence — the Barth approval and the heart-failure null stand in different populations with different endpoints, and neither erases the other. Secondary summaries err in both directions: overgeneralizing the null (“it doesn't work”) or burying it under the approval.
Our evidence-tier discipline exists for this: preclinical membrane data (tier: mechanistic), trial data (tier: clinical), and regulatory actions (tier: legal-institutional) are different kinds of claims. PROGRESS-HF is the textbook case of why keeping the tiers separate matters; the editorial policy defines them formally.
The neighboring record
The molecule's other broad-population programs tell the same story: MMPOWER-3 in primary mitochondrial myopathy and ReCLAIM in dry AMD (on our AMD page) completed without meeting primary endpoints, while TAZPOWER's genetically-stratified population produced the approval. The pattern is the most scientifically interesting fact in this molecule's public record — and it is visible only when the nulls are documented as carefully as the approval.
For researchers, the heart-failure record also anchors the safety literature: broad-population exposure is where cross-trial safety data comes from, feeding the aggregation on our elamipretide side effects page. The data-usage steps below handle null-result citation specifically.
How to use the data on this page
Step 1 — extract the parameters. Extract the null result's parameters, not just its direction: population (HFrEF), regimen as published, primary-endpoint definition, and the reported outcome. ‘Failed’ without these fields cannot be cited responsibly.
Step 2 — normalize before comparing. Normalize against the other programs before generalizing: a null in multifactorial heart failure and secondary-measure improvements in single-gene Barth syndrome are compatible results in different populations — the trials pillar's comparison table keeps the denominators visible.
Step 3 — grade the source. Grade the source: the primary PROGRESS-HF publication outranks press coverage and pipeline summaries. Where a secondary source narrates the trial without naming the endpoint, downgrade it — endpoint-free trial coverage is the signature of low-tier content.
Parameter comparison
PROGRESS-HF parameters from the public record.
| Parameter | Public record | Notes |
|---|---|---|
| Program | PROGRESS-HF | Heart failure program of elamipretide |
| Population | Heart failure with reduced ejection fraction | Broad, multifactorial cardiology population |
| Regimen as published | Daily subcutaneous administration | Per trial publication |
| Primary endpoint | Standard HFrEF outcome measure (see publication) | Endpoint definition is the citable datum |
| Result | Primary endpoint not met | Program concluded; no heart-failure indication exists |
| Relation to forzinity label | None — label derives from TAZPOWER | See fda page |
| Interpretive note | Mechanism-expression may be population-dependent | Literature discussion; marked as interpretation |
Table: PROGRESS-HF parameters from the public record. — compiled from public regulatory and academic sources; verify against the original documents before use.
Frequently asked questions
Did forzinity research show benefits in heart failure?
No. The PROGRESS-HF trial of elamipretide in heart failure with reduced ejection fraction completed without meeting its primary endpoint, and no heart-failure indication exists for the product. The approved indication research is Barth syndrome.
References
- PROGRESS-HF publication (PubMed indexed).
- Cardiac ss-31 preclinical bioenergetics literature (PubMed indexed).
- FDA forzinity prescribing information (indication section), accessdata.fda.gov.